IBRX · Large Cap · Healthcare · Biotechnology
Free AI brief
Free to track. No card required. Usually ready in 10-15 minutes.
Price, momentum, and the numbers behind the story.
Stocksbrew score
62/100
See the full financial picture
Open the five-year record, valuation checks and Wall Street view behind these scores.
Free for 3 days, then $9/mo. Cancel anytime.
Where the analysts and the crowd stand, and what it's worth to know first.
Current price
$10.11
Lowest
$12
Median target
$12
Highest
$15
What it earns and where it earns it, what you're paying for the stock, and the risk sitting on the balance sheet.
Current ratio
Strong · Good liquidity position
5.72x
Price / sales
Rich · Overpriced by revenue
67.19x
ROIC
Weak · Weak capital efficiency
-69.1%
IBRX against the names it's actually compared to.
| Company | Mkt cap | P/E | Rev growth | Score |
|---|---|---|---|---|
| $11.14B | - | +192.9% | 62 | |
| $10.02B | 19.1 | +19.7% | 78 | |
| $31.74B | 33.2 | +15.5% | 78 | |
| $4.23B | 12.7 | +13.5% | 78 | |
| $1.11T | 40.1 | +49.6% | 77 |
Every story that touched the stock this week, newest first.